-
Judge orders Meta to pay $25 bn to New Mexico in Cambridge Analytica case
-
UN experts urge Meta to safeguard political expression in Brazil election
-
Champagne puts cork in project to expand production area
-
Websites go dark worldwide as AI exposes critical security flaws
-
Canadian publisher says novelist Orelien used AI to write novel
-
Defense in Maradona death trial seeks acquittal of doctor
-
Trump faces fresh questions over ties to 'humanitarian' Putin
-
Jansen, Rabada put South Africa in sight of win over Australia
-
Hansen back in Ireland squad for Nations Championship
-
Low Rhine weighed on German growth: central bank
-
Kremlin sees little 'substance' in Ukraine peace ideas
-
OpenAI says its AI agents disabled their own safety monitors
-
Top Arab-Israeli election candidate tells AFP Netanyahu win would be 'catastrophe'
-
Alldritt returns as France call up seven newcomers for Nations Championship
-
South African rugby player's death due to 'aortic dissection'
-
UN issues call to arms to combat off-the-charts El Nino
-
France's Macron lands in Riyadh on surprise 'solidarity' visit
-
Nigeria Ebola case matches DR Congo strain
-
Around the world, far right blames immigrants for French protests
-
Musk's SpaceX helps launch stock market gains
-
South Africa eases fuel pain as growth slows
-
Rose salutes Bournemouth's past heroes ahead of AC Milan clash
-
Woody Allen shoots new movie in Madrid
-
Argentina's Milei calls Spain PM Sanchez a 'dictator' in Madrid visit
-
Nvidia's Huang urges Europe to go all in on AI
-
Barca's Olmo injured for a month, misses Clasico
-
Five things to know as French bond yield tops 5%
-
Impacts of UK's new North Sea gas drilling
-
'Complete threat' Ngumoha excites Liverpool captain Van Dijk
-
Jansen takes five for South Africa as Australia forced to follow on
-
'The fishing's terrible': Deforestation devastates C.Africa river
-
Toulouse v Troyes Ligue 1 game postponed as France gripped by unrest
-
France's tourism sector worried about impact of riots
-
PSG winger Kvaratskhelia's season in doubt after torn ACL
-
Macron takes aim at Trump for using France riots for election gain
-
Putin, Witkoff meet in Russia for Ukraine war talks
-
North Korea says 'new firepower units' in place, loudspeakers to return
-
Musk's SpaceX helps fuel stock market gains
-
Indonesia leader hits out at market downgrade warning
-
Authors urge UK to halt 'draconian' Palestine Action ban as Rooney sales end
-
Macron slams 'stupid' comments based on AI videos by leaders on France riots
-
South Korea guides crowd-pulling shark out of canal
-
'Public health crisis': Indonesians seek fire relief from state
-
PSG's Kvaratskhelia season in doubt after torn ACL
-
British Museum sells second set of Bayeux exhibition tickets
-
President berates countries that 'insult' Indonesia over wildfires
-
Australian lawmaker loses both legs after 'targeted' attack
-
PSG's Kvaratskhelia set for months out with torn ACL
-
UK approves drilling in controversial Jackdaw gas field
-
Japan sends senior diplomat to Russia over detained journalist
Hemogenyx Pharmaceuticals PLC Announces Notice of AGM
Hemogenyx Pharmaceuticals plc
("Hemogenyx Pharmaceuticals" or the "Company")
Posting of Annual Report & Notice of Annual General Meeting
LONDON, UK / ACCESS Newswire / June 5, 2026 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group, confirms that the Annual Report and Accounts for the year ended 31 December 2025, the Notice of the Annual General Meeting ("AGM") and a Form of Proxy will be posted to shareholders today and will shortly be available on the Company's website at https://hemogenyx.com/investors/annual-half-year-reports/.
The AGM is to be held on 30 June 2026 at 2.00 pm BST at One Heddon Street, London, W1B 4BD.
Enquiries:
Hemogenyx Pharmaceuticals plc | |
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder | |
Peter Redmond, Director | |
SP Angel Corporate Finance LLP | Tel: +44 (0)20 3470 0470 |
Matthew Johnson, Vadim Alexandre, Adam Cowl | |
AlbR Capital Limited | Tel: +44 (0)20 7469 0930 |
Lucy Williams, Duncan Vasey, Charles Goodfellow | |
About Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals is a publicly traded company (LSE:HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City.
The Company is a clinical-stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as platform technologies that it uses as engines for novel product development.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
SOURCE: Hemogenyx Pharmaceuticals plc
View the original press release on ACCESS Newswire
A.Mahlangu--AMWN